Please upgrade your browser.
Recent report of MET inhibition strengthened the role of c–Met inhibition across pRCC.
Brian I. Rini, MD, presents a case study focused on the treatment of a 64 year-old male who presented with recurrent lung nodules 9 years after a left radical nephrectomy for a clear-cell renal cell carcinoma (RCC).
Patients with high cholesterol had a 43 percent lower risk of dying.
Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors
Deciphera Pharmaceuticals a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET TIE2 VEGFR2 and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies.
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...
Nearly half of respondents report losing access to doctors, hospitals, and treatments
Prof Swanton discusses his presentation at the recent European International Kidney Cancer Symposium sponsored by US based Kidney Cancer Association
Madison-based biotech firm Centrose received a six-month $224,734 grant...
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.
|Powered by NeonCRM|